Lancet Rheumatology SCIE

文章名称引用次数

• Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial51
• Management of IgG4-related disease16
• Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial9
• Risk factors for dislocation after primary total hip replacement: a systematic review and meta-analysis of 125 studies involving approximately five million hip replacements8
• Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial7
• IgG4-related disease in the Japanese population: a genome-wide association study7
• Symptom-based stratification of patients with primary Sjogren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials6
• Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials6
• The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program6
• Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials5